Matt Browne

Matt’s practice focuses on transactional and general corporate matters, with Matt typically serving as his clients’ first point of contact at Cooley for all matters and regularly working with them on mergers and acquisitions, public and private securities offerings, public company reporting and disclosure issues, corporate governance matters, and other commercial matters.

Matt’s clients include companies in the software, cybersecurity, healthcare, semiconductor, financial technology, consumer products, medical devices, diagnostics, and biotechnology industries.

Matt’s recent engagements include:

• AttackIQ: acquisition of the assets of DeepSurface
• Mission Secure: sale to ServiceNow
• Cortica: $80 million financing
• TriSalus: warrant exchange tender offer for special purpose acquisition company (SPAC) warrants
• TriSalus: $50 million senior secured credit facility with OrbiMed
• Cirrus Bio: sale to Maverix Medical
• Talphera: partial monetization of Dsuvia royalties and milestones to XOMA Royalty
• MannKind: partial monetization of Tyvaso DPI royalties to Sagard Healthcare
• Ovid Therapeutics: partial monetization of soticlestat royalties to Ligand Pharmaceuticals
• TriSalus: de-SPAC transaction with MedTech Acquisition Corporation
• Cortica: acquisition of Springtide Child Development and $75 million Series D financing
• TRACON Pharmaceuticals: $30 million litigation financing
• Athenex: sale of Klisyri revenue interests to Sagard Healthcare and Oaktree Capital
• Sixth Street: $250 million royalty financing on sales of Ayvakit/Ayvakyt and Blu-263 and $400 million senior secured credit facility
• AgileThought: de-SPAC transaction with LIV Capital Acquisition Corp.
• Confluence Technologies: representation of Confluence Technologies’ management team in acquisition of company by Clearlake Capital
• Billtrust: de-SPAC transaction with South Mountain Merger Corp.
• XMatters: sale to Everbridge
• AttackIQ: $44 million Series C financing
• Cortica: $60 million Series C financing
• Paradigm Diagnostics: sale to Exact Sciences
• Viomics: sale to Exact Sciences
• Verb Surgical: sale to Johnson & Johnson
• TPG Sixth Street Partners: sale of Kadcyla royalties
• MedImpact: cash tender offer for all outstanding equity held by non-affiliates

Matt is on the board of directors and executive committee of the Corporate Directors Forum and the executive committee of Connect San Diego. He is also a former trustee of the Sanford Burnham Prebys Medical Discovery Institute. At Cooley, Matt is a member of the risk management committee and previously served on the opinion committee and partnership nominating committee.

Before joining Cooley in 1999, Matt was an associate at a US-based international law firm.